Strategies for Improving Enrollment of Diverse Populations with a Focus on Lipid-Lowering Clinical Trials

Oluwabunmi Ogungbe, Jelani K. Grant, Adeoluwa Segilola Ayoola, Eyram Bansah, Hailey N. Miller, Timothy B. Plante, Payam Sheikhattari, Yvonne Commodore-Mensah, Ruth Alma N. Turkson-Ocran, Stephen P. Juraschek, Seth S. Martin, Michael Lin, Cheryl R. Himmelfarb, Erin D. Michos

Research output: Contribution to journalReview articlepeer-review

Abstract

Purpose of Review: We review under-representation of key demographic groups in cardiovascular clinical trials, focusing on lipid-lowering trials. We outline multilevel strategies to recruit and retain diverse populations in cardiovascular trials. Recent Findings: Barriers to participation in trials occur at the study, participant, health system, sponsor, and policy level, requiring a multilevel approach to effectively increase participation of under-represented groups in research. Increasing the representation of marginalized and under-represented groups in leadership positions in clinical trials can ensure that their perspectives and experiences are considered. Trial design should prioritize patient- and community-indicated needs. Summary: Women and individuals from racially/ethnically diverse populations remain under-represented in lipid-lowering and other cardiovascular clinical trials relative to their disease burden in the population. This limits the generalizability of trial results to the broader population in clinical practice. Collaboration between community stakeholders, researchers, and community members can facilitate shared learning about trials and build trust.

Original languageEnglish (US)
Pages (from-to)1189-1210
Number of pages22
JournalCurrent Cardiology Reports
Volume25
Issue number10
DOIs
StatePublished - Oct 2023

Keywords

  • Clinical trials
  • Diversity
  • Under-representation
  • Women

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Strategies for Improving Enrollment of Diverse Populations with a Focus on Lipid-Lowering Clinical Trials'. Together they form a unique fingerprint.

Cite this